The House Committee on Oversight and Government Reform has asked five drug and medical device companies for documents on their marketing practices. The requests are part of the subcommittee’s heightened oversight of marketing in the drug and device industry.
Letters were sent to Eli Lilly, AstraZeneca, Boston Scientific, Cordis and Cephalon.
The letters ask for information on clinical trials, compensation to experts, explanations for why some unpublished studies were not published, any marketing department support for studies, information given to company and consultant sales personnel, and other items.
From the May 01, 2007 Issue of MM+M - Medical Marketing and Media
